Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Combined detection of dickkopf-1 subtype classification autoantibodies as biomarkers for the diagnosis and prognosis of non-small cell lung cancer.

Shen L, Wu X, Tan J, Gu M, Teng Y, Wang Z, Yue W.

Onco Targets Ther. 2017 Jul 18;10:3545-3556. doi: 10.2147/OTT.S134162. eCollection 2017.

2.

Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology.

Kagey MH, He X.

Br J Pharmacol. 2017 Dec;174(24):4637-4650. doi: 10.1111/bph.13894. Epub 2017 Jul 7. Review.

3.

Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?

Mazon M, Masi D, Carreau M.

Cancers (Basel). 2016 Jun 28;8(7). pii: E62. doi: 10.3390/cancers8070062. Review.

4.

Serum dickkopf-1 as a biomarker in screening gastrointestinal cancers: a systematic review and meta-analysis.

Liang B, Zhong L, He Q, Wang S, Pan Z, Wang T, Zhao Y.

Onco Targets Ther. 2015 Oct 22;8:3115-22. doi: 10.2147/OTT.S93152. eCollection 2015.

5.

Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma.

Xu Y, Chen B, George SK, Liu B.

RNA Biol. 2015;12(12):1314-22. doi: 10.1080/15476286.2015.1094600.

6.

Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia.

Calkoen FG, Vervat C, Eising E, Vijfhuizen LS, 't Hoen PB, van den Heuvel-Eibrink MM, Egeler RM, van Tol MJ, Ball LM.

Haematologica. 2015 Nov;100(11):1434-41. doi: 10.3324/haematol.2015.126938. Epub 2015 Aug 20.

7.

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic.

Hoang MD, Jung SH, Lee HJ, Lee YK, Nguyen-Pham TN, Choi NR, Vo MC, Lee SS, Ahn JS, Yang DH, Kim YK, Kim HJ, Lee JJ.

Chonnam Med J. 2015 Apr;51(1):1-7. doi: 10.4068/cmj.2015.51.1.1. Epub 2015 Apr 14. Review.

8.

Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts.

Nierste BA, Glackin CA, Kirshner J.

Am J Blood Res. 2014 Dec 15;4(2):73-85. eCollection 2014.

9.

Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D 2 (300,000 IU).

Sankaralingam A, Roplekar R, Turner C, Dalton RN, Hampson G.

J Osteoporos. 2014;2014:682763. doi: 10.1155/2014/682763. Epub 2014 Nov 24.

10.

Potential prognostic, diagnostic and therapeutic markers for human gastric cancer.

Tsai MM, Wang CS, Tsai CY, Chi HC, Tseng YH, Lin KH.

World J Gastroenterol. 2014 Oct 14;20(38):13791-803. doi: 10.3748/wjg.v20.i38.13791. Review.

11.

Molecular changes in pre-metastatic lymph nodes of esophageal cancer patients.

Otto B, Koenig AM, Tolstonog GV, Jeschke A, Klaetschke K, Vashist YK, Wicklein D, Wagener C, Izbicki JR, Streichert T.

PLoS One. 2014 Jul 21;9(7):e102552. doi: 10.1371/journal.pone.0102552. eCollection 2014.

12.

Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.

Li R, Qian J, Zhang W, Fu W, Du J, Jiang H, Zhang H, Zhang C, Xi H, Yi Q, Hou J.

Br J Haematol. 2014 Sep;166(5):690-701. doi: 10.1111/bjh.12943. Epub 2014 May 14.

13.

Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.

Zhou F, Meng S, Song H, Claret FX.

Blood Rev. 2013 Nov;27(6):261-7. doi: 10.1016/j.blre.2013.08.002. Epub 2013 Sep 2. Review.

14.

Immunotherapy strategies for multiple myeloma: the present and the future.

Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA.

Immunotherapy. 2013 Sep;5(9):1005-20. doi: 10.2217/imt.13.97. Review.

15.

New strategies in the treatment of multiple myeloma.

Munshi NC, Anderson KC.

Clin Cancer Res. 2013 Jul 1;19(13):3337-44. doi: 10.1158/1078-0432.CCR-12-1881. Epub 2013 Mar 20. Review.

16.

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.

Wang L, Qian J, Lu Y, Li H, Bao H, He D, Liu Z, Zheng Y, He J, Li Y, Neelapu S, Yang J, Kwak LW, Yi Q, Cai Z.

Haematologica. 2013 Sep;98(9):1458-66. doi: 10.3324/haematol.2012.071340. Epub 2013 Mar 18.

17.
18.

DKK1 as a novel target for myeloma immunotherapy.

Qian J, Yi Q.

Oncoimmunology. 2012 Aug 1;1(5):756-758.

19.

Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion.

Wang L, Zhao Y, Qian J, Sun L, Lu Y, Li H, Li Y, Yang J, Cai Z, Yi Q.

Cancer. 2013 Feb 15;119(4):782-91. doi: 10.1002/cncr.27792. Epub 2012 Aug 22.

20.

Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Danylesko I, Beider K, Shimoni A, Nagler A.

Clin Dev Immunol. 2012;2012:753407. doi: 10.1155/2012/753407. Epub 2012 May 10. Review.

Supplemental Content

Support Center